Further, recent studies have linked activating PI3Kα mutations to enhanced Rac1 and Yap signaling during breast cancer progression in vivo54,55 and suggest an invasive program that may be potentiated by mechanical alterations to the ECM that commonly occur during breast tumor progression. The gene discussed is RAC1; the disease is breast carcinoma.